StockData
Adagene Inc. logo

Adagene Inc. (ADAG) stock

ADAGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 5/30
$1.48−0.12 (-7.50%)

Close on Nov 17, 2026Market cap $87.66MP/E –Yield –

Adagene r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $22.03M, down 23.4% from the year before. The highest annual figure on record is $81.34M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$22.03M-23.4%
FY2024Dec 31, 2024$28.78M-21.4%
FY2023Dec 31, 2023$36.64M-55.0%
FY2022Dec 31, 2022$81.34M+19.4%
FY2021Dec 31, 2021$68.10M+103.1%
FY2020Dec 31, 2020$33.54M+106.9%
FY2019Dec 31, 2019$16.21M+0.8%
FY2018Dec 31, 2018$16.08M–

More Adagene figures

See a number that looks wrong?